Pharvaris (PHVS) Competitors

Pharvaris logo
$31.28 -0.38 (-1.20%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$32.00 +0.72 (+2.30%)
As of 11/20/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PHVS vs. PTGX, RYTM, ABVX, ALKS, and KNSA

Should you buy Pharvaris stock or one of its competitors? Pharvaris's main competitors and comparable companies include Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Alkermes (ALKS), and Kiniksa Pharmaceuticals International (KNSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pharvaris compare to Protagonist Therapeutics?

Pharvaris (NASDAQ:PHVS) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Protagonist Therapeutics has a net margin of 62.04% compared to Pharvaris' net margin of 0.00%. Protagonist Therapeutics' return on equity of 42.83% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -67.97% -61.57%
Protagonist Therapeutics 62.04%42.83%40.29%

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pharvaris currently has a consensus price target of $59.53, indicating a potential upside of 90.32%. Protagonist Therapeutics has a consensus price target of $166.67, indicating a potential upside of 37.29%. Given Pharvaris' higher possible upside, analysts plainly believe Pharvaris is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Protagonist Therapeutics
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.94

In the previous week, Pharvaris had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 12 mentions for Pharvaris and 11 mentions for Protagonist Therapeutics. Pharvaris' average media sentiment score of 0.85 beat Protagonist Therapeutics' score of 0.24 indicating that Pharvaris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharvaris
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protagonist Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Protagonist Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$198.79M-$3.12N/A
Protagonist Therapeutics$46.02M172.18-$130.15M$4.7225.72

Pharvaris has a beta of -2.48, indicating that its share price is 348% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Pharvaris on 11 of the 15 factors compared between the two stocks.

How does Pharvaris compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Rhythm Pharmaceuticals currently has a consensus price target of $141.67, indicating a potential upside of 26.08%. Pharvaris has a consensus price target of $59.53, indicating a potential upside of 90.32%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe Pharvaris is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77
Pharvaris
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87

Pharvaris has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -69.03%. Pharvaris' return on equity of -67.97% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-69.03% -171.16% -43.00%
Pharvaris N/A -67.97%-61.57%

Rhythm Pharmaceuticals has higher revenue and earnings than Pharvaris. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$189.76M41.05-$196.54M-$2.90N/A
PharvarisN/AN/A-$198.79M-$3.12N/A

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Pharvaris. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 12 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.85 beat Rhythm Pharmaceuticals' score of 0.28 indicating that Pharvaris is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pharvaris
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rhythm Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.48, meaning that its share price is 348% less volatile than the broader market.

Summary

Rhythm Pharmaceuticals beats Pharvaris on 7 of the 13 factors compared between the two stocks.

How does Pharvaris compare to Abivax?

Pharvaris (NASDAQ:PHVS) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Pharvaris' return on equity of -67.97% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -67.97% -61.57%
Abivax N/A -91.69%-71.96%

In the previous week, Pharvaris had 2 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Pharvaris and 10 mentions for Abivax. Pharvaris' average media sentiment score of 0.85 beat Abivax's score of 0.47 indicating that Pharvaris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharvaris
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abivax
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pharvaris currently has a consensus target price of $59.53, suggesting a potential upside of 90.32%. Abivax has a consensus target price of $155.00, suggesting a potential upside of 110.82%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than Pharvaris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

Abivax is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$198.79M-$3.12N/A
AbivaxN/AN/A-$380.27M-$6.06N/A

Pharvaris has a beta of -2.48, meaning that its share price is 348% less volatile than the broader market. Comparatively, Abivax has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Pharvaris beats Abivax on 9 of the 14 factors compared between the two stocks.

How does Pharvaris compare to Alkermes?

Pharvaris (NASDAQ:PHVS) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Alkermes has higher revenue and earnings than Pharvaris. Alkermes is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$198.79M-$3.12N/A
Alkermes$1.48B5.12$241.66M-$0.02N/A

Pharvaris has a beta of -2.48, indicating that its stock price is 348% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Pharvaris has a net margin of 0.00% compared to Alkermes' net margin of -0.02%. Alkermes' return on equity of 0.40% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -67.97% -61.57%
Alkermes -0.02%0.40%0.19%

In the previous week, Pharvaris had 8 more articles in the media than Alkermes. MarketBeat recorded 12 mentions for Pharvaris and 4 mentions for Alkermes. Pharvaris' average media sentiment score of 0.85 beat Alkermes' score of 0.05 indicating that Pharvaris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharvaris
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

95.2% of Alkermes shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pharvaris presently has a consensus target price of $59.53, suggesting a potential upside of 90.32%. Alkermes has a consensus target price of $55.73, suggesting a potential upside of 24.02%. Given Pharvaris' stronger consensus rating and higher possible upside, research analysts plainly believe Pharvaris is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

Summary

Pharvaris and Alkermes tied by winning 8 of the 16 factors compared between the two stocks.

How does Pharvaris compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Pharvaris (NASDAQ:PHVS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 11.8% of Pharvaris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiniksa Pharmaceuticals International$677.56M10.89$59.01M$1.3072.22
PharvarisN/AN/A-$198.79M-$3.12N/A

Kiniksa Pharmaceuticals International currently has a consensus price target of $102.38, suggesting a potential upside of 9.04%. Pharvaris has a consensus price target of $59.53, suggesting a potential upside of 90.32%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe Pharvaris is more favorable than Kiniksa Pharmaceuticals International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiniksa Pharmaceuticals International
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80
Pharvaris
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87

Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.48, meaning that its stock price is 348% less volatile than the broader market.

In the previous week, Pharvaris had 4 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 12 mentions for Pharvaris and 8 mentions for Kiniksa Pharmaceuticals International. Pharvaris' average media sentiment score of 0.85 beat Kiniksa Pharmaceuticals International's score of 0.81 indicating that Pharvaris is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kiniksa Pharmaceuticals International
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pharvaris
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kiniksa Pharmaceuticals International has a net margin of 11.58% compared to Pharvaris' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 17.27% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiniksa Pharmaceuticals International11.58% 17.27% 12.64%
Pharvaris N/A -67.97%-61.57%

Summary

Kiniksa Pharmaceuticals International beats Pharvaris on 10 of the 15 factors compared between the two stocks.

Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHVS vs. The Competition

MetricPharvarisBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.05B$3.92B$7.43B$10.86B
Dividend YieldN/A3.79%2.51%4.77%
P/E Ratio-10.0323.0732.5628.75
Price / SalesN/A15.468.105.41
Price / CashN/A21.9220.2520.77
Price / Book6.714.124.343.51
Net Income-$198.79M-$24.08M$3.51B$394.12M
7 Day Performance-6.24%-9.85%-8.07%-8.97%
1 Month Performance1.96%-12.77%-10.29%-11.61%
1 Year Performance25.98%-7.99%-4.70%-11.21%

Pharvaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHVS
Pharvaris
3.477 of 5 stars
$31.28
-1.2%
$59.53
+90.3%
+26.0%$2.05BN/AN/A148
PTGX
Protagonist Therapeutics
2.7722 of 5 stars
$136.26
+0.3%
$166.67
+22.3%
+42.2%$8.82B$46.02M28.87141
RYTM
Rhythm Pharmaceuticals
2.2207 of 5 stars
$113.95
+0.0%
$142.00
+24.6%
+10.4%$7.90B$189.76MN/A414
ABVX
Abivax
3.1895 of 5 stars
$90.00
+3.4%
$155.00
+72.2%
-38.3%$7.88BN/AN/A98
ALKS
Alkermes
2.2525 of 5 stars
$46.47
+0.6%
$55.06
+18.5%
+57.1%$7.81B$1.48BN/A2,050

Related Companies and Tools


This page (NASDAQ:PHVS) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners